Gene May Predict if Further Cancer Treatments are Needed

“A new predictive tool that could help patients with breast cancer and certain lung cancers decide whether follow-up treatments are likely to help is being developed by researchers. The findings offer insight into helping patients assess treatment risk. Radiation therapy and chemotherapy that can destroy tumors also can damage surrounding healthy tissue. So with an appropriate test, patients could avoid getting additional radiation or chemotherapy treatment they may not need.”

Editor’s note: This study was performed in mice, so it will be several years before patients can benefit from it. However, doctors are already using molecular testing to guide treatment decisions, often for patients with advanced lung cancer. For early-stage patients, the Pervenio test can help determine whether lung cancer is likely to return after surgery, which can let doctors know to consider preventive (“adjuvant”) treatments.

Study of ‘Super Responder’ Reveals Possible New Gene Target for Lung Cancer

“A potential new gene mutation that might drive lung cancer development and growth has been identified by researchers at The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC-James).

“A multi-institutional team led by OSUCCC-James researchers reports the findings in the Journal of Clinical Investigation. The study describes a patient with advanced lung cancer who was treated with the targeted drug sorafenib while on a clinical trial. Within two months, she demonstrated a near complete response, and she remained progression-free and asymptomic for five years while continuing to take sorafenib by mouth.”

Prostate Cancer Advance Could Improve Treatment Options

“Researchers have made an important advance in understanding genetic changes associated with terminal prostate cancer. The research highlights why relapses could happen in some men following hormone therapy. And it could help identify those patients that will develop fatal prostate cancer much earlier for life-extending therapy.”